Abstract:
The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in the prevention and treatment of gastrointestinal diseases and/or disorders.
Abstract:
A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. After addition of preservative and strength testing, the base solution is diluted to elixir strength. The elixir is then buffered to a pH range of about 7.2 to about 7.3 in order to maintain for an extended duration the semitransparent nature of the elixir.
Abstract:
A dietary supplement composition contains phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, and may, optionally, further contain Vitamin D, Vitamin B12, folate and Vitamin B6, provides components that have been linked to bone health.
Abstract:
A dietary supplement composition contains phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, and may, optionally, further contain Vitamin D, Vitamin B12, folate and Vitamin B6, provides components that have been linked to bone health.
Abstract:
The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
Abstract:
Liquid antacid compositions containing a tri- or di-ester buffer have a reduced final product pH providing for a more efficacious preservative system and better tasting product without compromising to acid neutralization capacity of the antacid.
Abstract:
Coolant compositions, flavorant compositions and ingestible and topical compositions containing at least one coolant compound selected from monomenthyl succinate, alkali metal salts of monomenthyl succinate, alkaline earth metal salts of monomenthyl succinate and mixtures thereof. These compositions are found to provide a pleasant, long-lasting cooling effect without bitterness and the cooling effect manifests itself differently than the cooling effect of other known coolants. As a result, a complementary or synergistic effect can by obtained by combination with other coolants. Further, the succinate-based coolant compounds of the invention are found to enhance the sensation of alcohol in alcoholic beverages.
Abstract:
A solid effervescent antacid formulation comprising as primary ingredients from about 35 to about 53 percent by weight of calcium carbonate, from about 0 to about 14 percent by weight of magnesium carbonate, from about 3.5 to about 7 percent by weight of a bicarbonate salt, from about 3.5 to about 7 percent by weight of malic acid and from about 21 to about 35 percent by weight of a bulking agent.
Abstract:
A method for promoting digestibility of a food product having an acid character which, when ingested, causes stimulation and hypersecretion of gastric and/or duodenum mucosae. The method comprises incorporating into the food product a sufficient amount of benzimidazole or a benzimidazole compound of the formula: ##STR1## where X and Y independently represent an alkyl group, a phenyl group or a halogen atom and n=1 to 4.
Abstract:
Disclosed is a pharmaceutical composition comprising a dextrin derivative in which a proportion of the hydroxyl groups of dextrin are replaced by basic groups. Such compositions are useful for the treatment of acidic conditions.